2010
Sedative-Hypnotics and Anxiolytics
Arnaout B, Petrakis I. Sedative-Hypnotics and Anxiolytics. 2010, 511-523. DOI: 10.1007/978-1-4419-0338-9_23.Peer-Reviewed Original ResearchCentral nervous system depressantsPsychiatric adverse eventsGroup of medicationsNon-benzodiazepine hypnoticsNon-medical useAdverse eventsSexual dysfunctionSleep disordersSedative hypnoticsPsychotic manifestationsCognitive disordersTherapeutic valueGeneral medicineAnxiety disordersMedicationsDisordersAnxiolyticsDeleterious effectsAbuseHypnoticsDysfunctionBenzodiazepinesEpidemiologyIntoxicationNeurology
1999
NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders
Krystal J, D'Souza C, Petrakis I, Belger A, Berman R, Charney D, AbiSaab W, Madonick S. NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders. Harvard Review Of Psychiatry 1999, 7: 125-143. PMID: 10483932, DOI: 10.3109/hrp.7.3.125.Peer-Reviewed Original ResearchConceptsN-methyl-D-aspartate (NMDA) subclassChronic pain syndromePain syndromeGlutamatergic dysfunctionNMDA agonistClinical studiesMajor depressionNMDA antagonistsGlutamate receptorsCoagonist siteParkinson's diseaseHuman psychopharmacological studiesPartial agonistAlzheimer's diseaseNeuropsychiatric conditionsNeuropsychiatric disordersDiseasePsychopharmacological studiesAnxiety disordersHuntington's diseaseAgonistsAntagonistTherapeutic hypothesesDisordersAddiction disorders